Previous close | 5.83 |
Open | 5.83 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 7.00 |
Expiry date | 2024-05-17 |
Day's range | 5.83 - 5.83 |
Contract range | N/A |
Volume | |
Open interest | 8 |
Amidst a significant net loss increase, Omeros Corp navigates through promising drug trials and strategic royalty milestones.
SEATTLE, May 15, 2024--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2024, which include: